Vaginal dryness affects up to 60% of postmenopausal women, but it’s not limited to menopause. It can show up during breastfeeding, after cancer treatment, from certain medications, or even during perimenopause in your early 40s (about 19% of women aged 40 to 45 experience it). The good news: several effective options exist, ranging from over-the-counter products you can start today to prescription treatments that restore tissue health over time.
Why Vaginal Dryness Happens
Estrogen is the primary driver of vaginal moisture. It keeps the vaginal lining thick, elastic, and well-lubricated by stimulating cell growth and maintaining a protective outer layer of tissue. When estrogen drops, the vaginal lining thins, cells shrink, and the tissue produces less of the protective keratin layer that shields it from friction and irritation. At the same time, enzyme activity increases in a way that breaks down tissue faster, and inflammatory immune cells flood the area, which can cause burning or soreness even without any obvious trigger.
These changes are progressive. Unlike hot flashes, which often improve on their own over time, vaginal dryness tends to get worse without treatment. The tissue becomes less elastic, more fragile, and more prone to small tears during everyday activities or sex.
Moisturizers vs. Lubricants
These two products solve different problems, and using the right one (or both) matters.
Vaginal moisturizers are applied regularly, typically one to three times a week, whether or not you’re sexually active. They adhere to the vaginal lining and pull water into the tissue, improving hydration, elasticity, and overall comfort between uses. Polycarbophil-based moisturizers have shown the strongest evidence for temporarily reducing dryness and atrophy symptoms. Think of these like a daily skin moisturizer for your face: they maintain baseline comfort.
Lubricants provide immediate, temporary relief during sexual activity by reducing friction. They don’t treat the underlying dryness. When choosing a lubricant, look for water-based products with an osmolality below 1,200 mOsm/kg and a pH between 3.8 and 4.5. Avoid products containing parabens, glycerin, added fragrances, or flavors, as these can irritate already-sensitive tissue. Silicone-based lubricants last longer and don’t need reapplication as often, but they aren’t compatible with silicone toys or devices.
If your dryness is mild or occasional, a combination of a regular moisturizer and lubricant during sex may be all you need. For moderate to severe symptoms, these products work best as a complement to other treatments rather than a standalone solution.
Hyaluronic Acid Gels
Hyaluronic acid, a compound the body naturally produces, is available as a vaginal gel without a prescription. It works by binding water molecules and drawing moisture into the tissue. A systematic review comparing hyaluronic acid to vaginal estrogen found that both significantly improved dryness, pain during sex, vaginal pH, and cell maturation. In most studies, estrogen outperformed hyaluronic acid overall, but several trials found no significant difference between the two for dryness specifically. One study even found hyaluronic acid was superior to estrogen for dryness, urinary incontinence, and a composite vaginal symptom score.
This makes hyaluronic acid a reasonable option if you want something more effective than a basic moisturizer but prefer to avoid hormones, or if hormonal treatments are contraindicated for you.
Low-Dose Vaginal Estrogen
For moderate to severe dryness, localized estrogen is the most effective treatment available. It restores the vaginal lining from the cellular level: thickening the tissue, rebuilding its protective layers, improving elasticity, and lowering vaginal pH back to its premenopausal range. Because it’s applied directly to the vaginal tissue, systemic absorption is minimal compared to oral hormone therapy.
It comes in three main forms:
- Vaginal inserts (tablets): Used daily for two weeks, then reduced to twice a week as maintenance.
- Vaginal ring: A flexible ring placed in the vagina that releases a steady, low dose of estrogen for three months before replacement.
- Vaginal cream: Applied on a schedule similar to the inserts, with dosing adjusted based on symptom response.
It typically takes at least two weeks of consistent use before the vaginal tissue begins to respond, and most women notice meaningful improvement by four weeks. Full results, including significant changes in tissue thickness and symptom scores, are usually apparent by 12 weeks. This isn’t a quick fix, but the results are cumulative and sustained with ongoing use.
Vaginal DHEA (Prasterone)
Prasterone is a vaginal insert containing DHEA, a hormone precursor that converts into both estrogen and testosterone directly within vaginal tissue. It’s used nightly as a small suppository. In clinical trials, prasterone significantly outperformed placebo across every measured outcome at 12 weeks. Vaginal pH dropped by roughly a full point (compared to almost no change with placebo), and the proportion of unhealthy, immature vaginal cells decreased by 42 to 47 percentage points versus only 2 to 12 points with placebo.
Because the hormonal conversion happens locally within the tissue, prasterone offers an alternative pathway to vaginal restoration that some women and their providers prefer over direct estrogen application.
Oral Non-Hormonal Prescription Options
Ospemifene is a daily pill that acts like estrogen on vaginal tissue without being estrogen. It belongs to a class of drugs that selectively activate estrogen receptors in certain tissues while blocking them in others. Clinical trials show it significantly increases vaginal tissue thickness, shifts the cell population from immature to mature cells, and lowers vaginal pH. A meta-analysis found it reduced immature vaginal cells by 37.5% and increased healthy superficial cells by about 9%.
This is a useful option for women who prefer an oral medication over vaginal application, though it isn’t appropriate for everyone, particularly those with a history of blood clots or certain hormone-sensitive cancers.
Physical Therapy and Mechanical Options
Pelvic floor physical therapy can play an important role, especially when dryness has led to pain during sex that causes the pelvic muscles to tighten reflexively. A skilled pelvic floor therapist can teach you to release that tension, which reduces pain independent of the dryness itself. Vaginal dilator training, often combined with pelvic floor therapy, helps preserve tissue elasticity by providing gentle, controlled stretching.
Regular vaginal penetration of any kind, whether from intercourse, lubricated fingers, or dilators, helps prevent the fibrotic (scarring) changes that develop in unused, estrogen-deprived tissue. This isn’t about “use it or lose it” as a slogan; it’s a documented mechanical effect. Gentle, consistent stretching preserves blood flow and flexibility in the vaginal walls.
Laser and Energy-Based Treatments
Fractional CO2 laser therapy is a newer in-office treatment that uses targeted heat to stimulate collagen production and tissue remodeling in the vaginal walls. An expert panel reviewing the available evidence concluded that for women with mild to moderate symptoms, these treatments are safe, effective, and well tolerated. Most women report low pain scores during the procedure, and the few who experience any discomfort after treatment find it resolves within two weeks.
Treatments are typically done in a series of three sessions spaced several weeks apart, with maintenance sessions once or twice a year. The main drawback is cost: laser treatments are rarely covered by insurance and can run several hundred dollars per session.
Options for Breast Cancer Survivors
Women with a history of hormone-sensitive breast cancer face a unique challenge because estrogen, the most effective treatment, may not be safe depending on the type of ongoing cancer therapy. Non-hormonal moisturizers and lubricants are the recommended first line, sometimes combined with pelvic floor therapy, dilators, or hyaluronic acid. Vitamin D and E vaginal suppositories and topical lidocaine (4%) have also shown safety and effectiveness in this population.
If non-hormonal approaches aren’t enough, the conversation gets more nuanced. The safety of vaginal estrogen depends heavily on the type of adjuvant therapy. For women taking tamoxifen, vaginal estrogen may carry less risk because of how tamoxifen interacts with estrogen receptors. For women on aromatase inhibitors, even small increases in circulating estrogen could theoretically affect residual cancer cells. In those cases, vaginal DHEA (prasterone) has been studied as a potentially safer alternative, though it also carries some theoretical risk since DHEA can convert to estrogen. Any hormonal treatment in this situation requires careful discussion with both a gynecologist and an oncologist.